EarlySight provides the Cellularis platform, an ophthalmic camera that uses adaptive‑optics trans‑scleral flood illumination to capture cellular‑resolution images of the retina and optic disc, revealing structures invisible to standard devices. The system offers multi‑mode imaging, widefield fundus registration, and joystick‑controlled fast acquisition, enabling ophthalmologists and researchers to detect, monitor, and assess eye disease biomarkers more precisely.
Funding
$3.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current ophthalmic imaging devices lack the resolution to visualize retinal cells and layers, leading to delayed diagnosis and suboptimal monitoring of eye diseases that cause vision loss for over 200 million people worldwide.
Solution
EarlySight has created the Cellularis platform, an ophthalmic camera that combines trans‑scleral flood illumination with adaptive optics (AO‑TFI) to capture cellular‑level images of the retina and optic disc. The system provides high‑resolution views of the retinal pigment epithelium, photoreceptors, nerve‑fiber layer, and retinal vessels, revealing structures invisible to standard instruments. A widefield fundus overview is acquired simultaneously, enabling precise localization for follow‑up examinations. The device features a joystick‑controlled, quick acquisition workflow that is comfortable for patients and easy for clinicians. EarlySight is developing AI‑driven software to automatically quantify structural biomarkers from these images, supporting objective disease detection, progression tracking, and treatment assessment.
Target Audience
Primary customers are ophthalmologists, retinal specialists, and research institutions that require high‑resolution retinal imaging for diagnosis, monitoring, and clinical trial evaluation of degenerative eye diseases.
Features
- Adaptive‑optics trans‑scleral flood illumination delivering cellular‑resolution images up to 10× finer than conventional clinical cameras
- Multi‑mode imaging modes for targeted visualization of RPE, photoreceptors, nerve‑fiber layer, and retinal vessels
- Integrated widefield fundus capture for rapid area registration and repeatable follow‑up imaging
- Manual joystick operation with fast (seconds‑scale) acquisition for a familiar, efficient exam experience
- Automatic storage of image coordinates within the eye to streamline longitudinal monitoring
- Planned AI analytics pipeline for objective measurement of cellular biomarkers and disease progression